secwatch / observer
8-K filed May 17, 2024, 7:59 PM ET CIK 0001505512
other material confidence high sentiment neutral materiality 0.60

Regulus shareholders approve 2019 Equity Plan amendment adding 9.5M shares

Regulus Therapeutics Inc.

item 5.02item 5.07item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001193125-24-141703
form_type
8-K
ticker
null
cik
0001505512
company_name
Regulus Therapeutics Inc.
filed_at
2024-05-17T23:59:59+00:00
discovered_at
2026-05-14T18:03:18.720416+00:00
generated_at
2026-06-01T15:25:30.858386+00:00
sec_items
["5.02", "5.07", "9.01"]
event_type
other_material
sentiment
neutral
materiality_score
0.6
calibrated_materiality_score
0.6
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001193125-24-141703
json_url
https://secwatch.observer/filing/0001193125-24-141703.json
markdown_url
https://secwatch.observer/filing/0001193125-24-141703.md
text_url
https://secwatch.observer/filing/0001193125-24-141703.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/0001193125-24-141703-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1505512/000119312524141703/d829869d8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

0d3843106d7379e0a512c22c762c28e683b41793

Regulus Therapeutics Inc. shareholders approved Approval of amendment to 2019 Equity Incentive Plan to increase authorized shares by 9,500,000 and modify automatic share reserve calculation. at the 2024-05-16 meeting.

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

92453f7d2359cba16edf7b099601d7aed7459ff1

Regulus Therapeutics Inc. shareholders approved Advisory vote on frequency of say-on-pay votes. Every year selected. at the 2024-05-16 meeting.

Proposal 4. The Company’s stockholders approved, on an advisory basis, every year as the preferred frequency for holding stockholder advisory votes on the compensation of the Company’s named executive officers. One year Two Years Three Years Abstentions Broker Non-Votes 38,380,997 10,261 36,660 79,471 3,688,130

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

d7edb813f81f25f3b537f93d1ce140feacbf031a

Regulus Therapeutics Inc. shareholders approved Advisory approval of named executive officer compensation. at the 2024-05-16 meeting.

Proposal 3. The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement for the Annual Meeting. Votes For Votes Against Abstentions Broker Non-Votes 38,219,586 223,139 66,215 3,688,130

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

f8e0c4d3db59f4f0be2298340d404381b9ae4795

Regulus Therapeutics Inc. shareholders approved Election of ten directors named in the filing. at the 2024-05-16 meeting.

Proposal 1. Election of Directors The ten persons listed below were elected as directors at the Annual Meeting, each to serve until the Company’s 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. Votes For Votes Withheld Broker Non-Votes David Baltimore, Ph.D. 38,149,013 359,927 3,688,120 Kathryn J. Collier 38,157,716 351,224 3,688,120 Joseph P. Hagan 38,375,891 133,049 3,688,120 Alice S. Huang, Ph.D. 37,595,731 913,209 3,688,120 Preston Klassen, M.D. 38,147,754 361,186 3,688,120 Jake R. Nunn 38,156,266 352,674 3,688,120 Stelios Papadopoulos, Ph.D. 38,147,155 361,785 3,688,120 William Rastetter, Ph.D. 37,568,471 940,469 3,688,120 Hugh Rosen, M.D., Ph.D. 38,157,572 351,368 3,688,120 Pascale Witz, MBA, MSc 37,834,247 674,693 3,688,120

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

f8f131d77a98aad87fa76ecb28273b6981b2d026

Regulus Therapeutics Inc. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024. at the 2024-05-16 meeting.

Proposal 2. The Company’s stockholders ratified the selection by the audit committee of the board of directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. Votes For Votes Against Abstentions 42,040,910 152,439 3,721

SEC 8-K Item 5.07 confidence 0.9 SEC evidence

Comparable filings

CRM

Salesforce shareholders approve 34M share equity plan increase, extend term to 2036, all directors re-elected

Salesforce, Inc. June 1, 2026, 4:43 PM ET other_material Items 5.07, 5.02, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

Advisory vote to approve the fiscal 2026 compensation of the Company’s named executive officers: For Against Abstain Broker Non-Votes 493,864,228 117,716,717 668,510 102,463,325

Filing page SEC filing

SIRI

Sirius XM shareholders approve 7.2M share increase in 2024 equity plan, elect directors

SIRIUS XM HOLDINGS INC. June 1, 2026, 4:28 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

Election of Directors The holders of our common stock elected the persons listed below as Class I directors. Votes Cast For Votes Withheld Broker Non-Votes Eddy W. Hartenstein 229,472,971 4,921,855 51,448,019 Kristina M. Salen 231,643,217 2,751,609 51,448,019 Jennifer C. Witz 230,660,585 3,734,241 51,448,019 The holders of our common stock elected the persons listed below as Class II directors. Votes Cast For Votes Withheld Broker Non-Votes Evan D. Malone 230,881,893 3,512,933 51,448,019 Jonelle Procope 210,894,725 23,500,101 51,448,019 Anjali Sud 213,150,753 21,244,073 51,448,019

Filing page SEC filing

ESPR

Esperion shareholders approve 7M-share increase to 2022 equity incentive plan

Esperion Therapeutics, Inc. June 1, 2026, 4:22 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

The Company’s stockholders approved Proposal 3. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 167,083,447 8,765,273 1,360,136 —

Filing page SEC filing

LUV

Southwest shareholders approve amended equity plan with 4.75M share increase; all directors elected

SOUTHWEST AIRLINES CO May 20, 2024, 7:59 PM ET other_material Items 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

3. Proposal 3 – Approval of the Southwest Airlines Co. Amended and Restated 2007 Equity Incentive Plan: VOTES FOR VOTES AGAINST ABSTENTIONS BROKER NON-VOTES 408,346,613 28,870,401 1,635,532 90,613,942

Filing page SEC filing

OSUR

OraSure shareholders approve 3M share increase in stock plan, charter amendment limiting officer liability

ORASURE TECHNOLOGIES INC May 17, 2024, 7:59 PM ET other_material Items 5.02, 5.03, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

ITEM 1 . Election of two Class III Directors for Terms Ending in 2027. NAME Votes For Votes Against Abstentions Broker Non-Votes Nancy J. Gagliano, M.D. 57,243,711 4,832,639 46,575 5,007,157 Lelio Marmora 57,332,773 4,732,865 57,287 5,007,157

Filing page SEC filing

HNI

HNI to close Hickory plant, consolidates production; charges $10.3M, saves ~$11M annually

HNI CORP May 20, 2024, 7:59 PM ET other_material Items 2.05, 2.06, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

Proposal No. 2 – Ratification of KPMG LLP as the Corporation’s Independent Registered Public Accounting Firm for Fiscal 2024. The Corporation’s shareholders ratified the selection of KPMG LLP as the Corporation’s independent registered public accounting firm for the fiscal year ending December 28, 2024, with votes as follows: %For 1 For Against Abstain 99.33% 41,551,173.283 281,975.938 62,933.098 1 Percentage of votes cast, which excludes abstentions (in accordance with Iowa law).

Filing page SEC filing

Nemaura Medical Inc.

Shareholders approve reverse stock split authorization at ratio of 1:10 to 1:150

Nemaura Medical Inc. May 17, 2024, 7:59 PM ET other_material Items 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.07, 9.01 same event type: other_material similar materiality

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

On May 9, 2024, the Shareholders of Nemaura Medical Inc. (the “Company”) approved by written consent to authorize amendments to the Articles of Incorporation of the Company (the “Articles”) to effect a reverse stock split of the common stock, par value $0.001 per share, of the Company (the “Common Stock”) ranging in ratio between 1-for-10 and 1-for-150, with one share of Common Stock being issued for a range of between each 10 and 150 shares of Common Stock issued and outstanding, with such final ratio to be determined by the Board following approval thereof by the shareholders of the Company, with any fractional shares of Common Stock resulting therefrom being rounded up to the nearest whole share of Common Stock (the “Reverse Split”), and to amend the Articles to effect the Reverse Split.

Filing page SEC filing

BRANDYWINE OPERATING PARTNERSHIP, L.P.

Brandywine extends revolver maturity to Dec 2026; shareholders OK 5M share increase for LTIP

BRANDYWINE OPERATING PARTNERSHIP, L.P. June 1, 2026, 4:30 PM ET other_material Items 1.01, 2.03, 5.02, 5.07, 9.01

same fact type: shareholder_vote same SEC item: 5.02, 5.07, 9.01 same event type: other_material

This filing

Proposal 5. The Company’s stockholders approved the Amended 2019 Plan which, among other things, increased the number of shares of our common stock authorized for issuance under the 2019 Plan by 9,500,000 shares and modified the calculation of the annual automatic share reserve increase to take into account shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants. Votes For Votes Against Abstentions Broker Non-Votes 32,563,555 5,916,084 29,301 3,688,130

Comparable filing

PROPOSAL 2. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for calendar year 2026. Votes For Votes Against Abstentions 134,853,955 7,100,190 646,621

Filing page SEC filing

Source: SEC EDGAR
accession 0001193125-24-141703
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.